-
Establishment of new drug R & D cooperation agreement between Sihuan pharmaceutical and to BBB
Time of Update: 2020-04-03
The cooperation to be carried out under the cooperation agreement will invest the research efforts of to BBB brain targeting technology and the group's R & D resources in the field of tumor and central nervous system.
-
Coating knowledge: coating R & D Engineer became the focus in July
Time of Update: 2020-04-03
Core tip: it is reported that the Ministry of environmental protection is speeding up the development of the 13th five year plan for environmental protection
Recently
-
Opening ceremony of Nippon Asia Pacific R & D Center Project
Time of Update: 2020-03-13
At 9:00 a.m
on March 12, 2020, the commencement ceremony of Nippon Asia Pacific R & D center and Nippon Innovation & R & D center project was ceremoniously held
-
R & D strategy and early R & D pipeline of Genentech
Time of Update: 2020-02-20
Source: reference [1] Genentech's early oncology research and development pipeline uses a variety of technology platforms, from traditional small molecule drugs to bispecific antibodies, personalized mRNA tumor vaccines, personalized T-cell therapy, to develop innovative therapies for the benefit of patients.
-
R & D daily essence pharmaceutical terminates two products R & D to cure diabetes or hope
Time of Update: 2020-02-20
The application for clinical trial of Lizhu medicine's monoclonal antibody IL-17A / F was approved; the combination therapy of ADC for bladder cancer was recognized by FDA
-
Xiamen issues measures to support the R & D and production of new coronavirus biomedicine
Time of Update: 2020-02-14
[policies and regulations of pharmaceutical network In order to novel coronavirus novel coronavirus, Xiamen has been combining with the local biomedical enterprises' basic
-
In the future, innovation in the pharmaceutical field will be the king, and the R & D investment of domestic pharmaceutical enterprises will grow steadily
Time of Update: 2020-02-11
[pharmaceutical network market analysis] in recent years, with the promotion of drug review reform, MAH, priority review and other policies, China's innovative drug industry has ushered in good opportunities for development.
-
AI pharmaceutical trend is obvious! What are the possibilities besides improving R & D Efficiency
Time of Update: 2020-02-06
In fact, new drug research and development cycle is long, investment is large, lasting for a long time, and efficiency is low, which has always been a "serious problem" in the field of medicine.
-
R & D Daily: moxifloxacin hydrochloride injection approved for marketing
Time of Update: 2020-01-15
Skyrizi's head to head phase 3 research reached the end point; Zhendong pharmaceutical's paracetamol tablet has been evaluated; Huabang pharmaceutical's bensulfobertastine tablet
-
In the first three quarters of 2019, the R & D expenditure of these three pharmaceutical companies ranked first
Time of Update: 2020-01-13
[trends of pharmaceutical network industry] in recent years, with the continuous promotion of medical reform policies such as volume procurement in China, the market growth
-
2020 R & D pipeline report: which areas deserve attention
Time of Update: 2020-01-02
2020 has come! At the beginning of the new decade, what are our expectations for the era of Biomedical Innovation? Recently, pharmaceutical executive released its 2020 Pipeline
-
In 2020, these R & D areas deserve the attention of pharmaceutical companies
Time of Update: 2020-01-02
In the past 20 years, the world's major pharmaceutical companies have invested hundreds of billions of dollars in the research and development of new Alzheimer's disease treatment drugs, and more than 320 drugs entering clinical research have failed.
-
Weisi medical transferred to scientific and technological innovation board, and there are hidden dangers in the proportion of R & D and sales
Time of Update: 2019-12-24
Original author: at that time, it was common for the three board enterprises to move to the science and technology innovation board
Would these three board enterprises
-
The R & D power of domestic drugs is increasing
Time of Update: 2019-12-24
Compared with developed countries, there is still a large gap in the level of drug R & D in China, with more follow-up R & D and relatively lack of breakthrough innovation
-
Readjustment of R & D pattern of pharmaceutical enterprises and operation focus of foreign enterprises
Time of Update: 2019-11-29
Under the background that the government encourages new drug research and development, Chinese cro and CMO enterprises will usher in more development opportunities and gain more market share.
-
Another multinational pharmaceutical company, China's early R & D center closed
Time of Update: 2019-11-19
On September 25, 2018, Novartis announced that it plans to cut more than 2200 jobs in its headquarters in Switzerland, which will affect 1500 front-line pharmaceutical production employees and about 700 employees in the commercial service department.
-
Dealway (China) Shanghai R & D center officially opened
Time of Update: 2019-11-11
Xiong Shaobo, deputy general manager of Fuda company, also said that in the future, Fuda company will work with dealway to make contributions to the R & D and innovation of thermal insulation materials and coating products.
-
International | aiside won the "Oscar" award of American science and technology circle - 100 innovation award of R & D
Time of Update: 2019-11-05
On November 1, axalta announced that its innovative voltatex ® 4224 high thermal conductivity impregnating resin won the "Oscar" award in the US scientific and technological
-
Dialogue with President of Takeda global R & D: is Takeda a M & A or R & D enterprise
Time of Update: 2019-11-03
"Before we mentioned that China joined the world, today we want China to help or even lead the world!" At a media communication meeting held by the center on October 29, Wang Yu
-
Yunnan Baiyao released the third quarter report, with increased R & D investment and emphasis on strengthening the layout of biological drugs
Time of Update: 2019-10-29
At present, there are 6 drugs under research in the pipeline of antibody pharmaceutical products in China, focusing on the field of immune diseases.
